Payment overview · 2025
General Payments
$281.08
3 reported records · 2 companies
Healthcare provider profile · identity verified
Mark Robert Anthony Britton, MD
Allopathic & Osteopathic Physicians|Hospitalist · TAVARES, FL · NPI 1497795959
Verified facts
What the public records show
CMS Open Payments records show Mark Robert Anthony Britton, MD received $281.08 in general payments during 2025 across 3 reported records.
Neurocrine BioSciences, Inc. accounted for 87.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $246.91 | 87.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.17 | 12.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.08 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $246.91 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 913 | 179 |
| Eliquis | Apixaban | 824 | 88 |
| Gabapentin | Gabapentin | 540 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 537 | 106 |
| Gemtesa | Vibegron | 337 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 327 | 56 |
| Trazodone Hcl | Trazodone Hcl | 311 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 68 |
| Carvedilol | Carvedilol | 289 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 286 | 64 |
| Lisinopril | Lisinopril | 264 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 47 |
| Furosemide | Furosemide | 231 | 54 |
| Losartan Potassium | Losartan Potassium | 190 | 46 |
| Sertraline Hcl | Sertraline Hcl | 185 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 184 | 37 |
| Jardiance | Empagliflozin | 182 | 18 |
| Mirtazapine | Mirtazapine | 171 | 47 |
| Divalproex Sodium | Divalproex Sodium | 156 | 29 |
| Metformin Hcl | Metformin Hcl | 153 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 146 | 47 |
| Famotidine | Famotidine | 142 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 34 |
| Potassium Chloride | Potassium Chloride | 135 | 30 |
| Xarelto | Rivaroxaban | 129 | 11 |
| Finasteride | Finasteride | 127 | 21 |
| Allopurinol | Allopurinol | 118 | 16 |
| Levetiracetam | Levetiracetam | 113 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 20 |
| Baclofen | Baclofen | 105 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 97 | 14 |
| Spironolactone | Spironolactone | 93 | 26 |
| Montelukast Sodium | Montelukast Sodium | 92 | 15 |
| Entresto | Sacubitril/Valsartan | 89 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 14 |
| Oxcarbazepine | Oxcarbazepine | 86 | 17 |
| Bumetanide | Bumetanide | 83 | 18 |
| Latanoprost | Latanoprost | 83 | 19 |
| Buspirone Hcl | Buspirone Hcl | 81 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 81 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 12 |
| Donepezil Hcl | Donepezil Hcl | 74 | 26 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 74 | 22 |
| Memantine Hcl | Memantine Hcl | 74 | 16 |
| Methocarbamol | Methocarbamol | 73 | 34 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 14 |
| Clonidine Hcl | Clonidine Hcl | 70 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 70 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | suppressed |
| Omeprazole | Omeprazole | 63 | 19 |
| Risperidone | Risperidone | 63 | 11 |
| Santyl | Collagenase Clostridium Hist. | 63 | 28 |
| Tramadol Hcl | Tramadol Hcl | 63 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 17 |
| Midodrine Hcl | Midodrine Hcl | 62 | 27 |
| Farxiga | Dapagliflozin Propanediol | 61 | 12 |
| Tradjenta | Linagliptin | 58 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 17 |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 22 |
| Insulin Aspart Flexpen | Insulin Aspart | 52 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 16 |
| Klor-Con 10 | Potassium Chloride | 50 | suppressed |
| Lorazepam | Lorazepam | 50 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 28 |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Lactulose | Lactulose | 47 | 13 |
| Nystatin | Nystatin | 45 | 26 |
| Ranolazine Er | Ranolazine | 43 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 28 |
| Sodium Chloride | 0.9 % Sodium Chloride | 42 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 11 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Meloxicam | Meloxicam | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 35 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 32 | 22 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Prednisone | Prednisone | 32 | 21 |
| Simvastatin | Simvastatin | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | 11 |
| Torsemide | Torsemide | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 12 |
| Timolol Maleate | Timolol Maleate | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 18 |
| Levofloxacin | Levofloxacin | 27 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Levemir | Insulin Detemir | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 16 |
| Procrit | Epoetin Alfa | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 17 |
| Ammonium Lactate | Ammonium Lactate | 24 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 17 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 24 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 22 | 13 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 14 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 20 | 16 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ertapenem | Ertapenem Sodium | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Cefepime | Cefepime In Iso-Osm Dextrose | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Glucagon Emergency Kit | Glucagon | 16 | 11 |
| Metolazone | Metolazone | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 11 |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.08 · 3 records | Neurocrine BioSciences, Inc. | INGREZZA, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error